Shire speaks (note the "new therapeutic areas" for Iplex)
Vickers cannot say whether Shire (NASDAQ:SHPGY) will be pursuing other acquisitions in the neonatalogy field because the company’s policy is not to disclose M&A targets.
“[Neonatalogy] is an area that we are interested in given the acquisition of this product,” he said.
Vickers also couldn’t comment on other new therapeutic areas for its protein replacement therapy that Shire may be looking to enter.
“At any point in time,” he said, “we are always involved in evaluations and discussions that may be at varied stages of advancement, some of which may ultimately result in deals that we will announce.”
Shire, which is based in Dublin, Ireland, has it U.S. headquarters in Wayne. The company’s human genetic therapies division is in Lexington, Mass.